The health-focused artificial intelligence venture Basecamp Research has secured a $60 million investment. The company’s Series B funding round was led by Singular. The UK-based Basecamp Research’s funding round also included participation from S32, Redalpine, André Hoffmann from Roche, Feike Sijbesma from Royal Philips, Paul Polman from Unilever, True Ventures, and Hummingbird Ventures.
Basecamp Research announced that it will use the new investment to accelerate data collection, expand its core dataset, enhance its artificial intelligence capabilities, improve its computational infrastructure, and increase its capacity to solve complex biological tasks.
Founded in 2019 by Glen Gowers and Oliver Vince, Basecamp Research focuses on the exploration and analysis of biological systems, providing solutions for drug development processes.
The company is enhancing the quality of data used in drug research by providing datasets that contain biological systems that are 100 times more advanced. On one hand, it can perform complex tasks, such as predicting protein structures and making enzyme design programmable, by utilizing AI technologies like AlphaFold-2.
On the other hand, the life sciences and pharmaceutical industries are in need of faster and more effective solutions. In this context, the importance of the company is once again highlighted, as Basecamp Research accelerates data collection and analysis processes, contributing to quicker scientific discoveries.
Source
Arwen Volkov, A graduate of the University of St. Gallen in Switzerland with a degree in International Finance, Arwen specializes in sustainable finance and green investments. She began her career at an investment bank in London, where she developed financing models for environmentally friendly projects. Known for her analytical and strategic thinking skills, Arwen is a sought-after financial consultant. In her spare time, she mentors fintech startups, contributing to their growth strategies. She is also a nature enthusiast and an amateur photographer.
